Italian AAV biotech closes $65M Series A; GSK's Jemperli nabs priority review in endometrial cancer
AAVantgarde, a Milan-based AAV biotech, has closed a €61 million ($65.1 million) Series A round.
The biotech currently has two AAV platforms, one using DNA recombination and another that trans-splices proteins, with treatment targets in ophthalmology. AAVantgarde is seeking to validate its two lead platforms, tagging the funds for a proof-of-concept study and further development.
“This financing represents a hallmark moment in our mission to help patients and we are excited to work with both our new and founding investors to advance our platforms and pipeline. The completion of this round with such a high-caliber group of global life science investors is a recognition of the significance of AAVantgarde’s unique technology, which will initially be utilized to help patients suffering with the debilitating impact of blindness associated with Usher1B syndrome and Stargardt disease,” CEO Natalia Misciattelli said in a release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.